News headlines about Merrimack Pharmaceuticals (NASDAQ:MACK) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.9632313907541 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
MACK stock traded down $1.03 during trading hours on Friday, hitting $8.29. The stock had a trading volume of 359,834 shares, compared to its average volume of 117,590. The firm has a market cap of $124.36, a P/E ratio of 0.23 and a beta of 1.59. Merrimack Pharmaceuticals has a fifty-two week low of $8.25 and a fifty-two week high of $39.90.
Separately, Robert W. Baird reaffirmed a “hold” rating and set a $12.00 price target on shares of Merrimack Pharmaceuticals in a research note on Thursday, March 15th.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3297342/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-merrimack-pharmaceuticals-mack-stock-price.html.
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.